{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:27:53Z","timestamp":1758806873774,"version":"3.40.5"},"reference-count":16,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2,1]]},"abstract":"<jats:sec>\n                  <jats:title>BACKGROUND:<\/jats:title>\n                  <jats:p>Tapentadol (Nucynta) is indicated for the treatment of moderate to severe pain in adults. Tapentadol\u2019s mechanism of action consists of acting as an agonist on the \u03bc-opioid receptor and by inhibiting the reuptake of norepinephrine. There are no published reports on the toxicity of tapentadol in pediatric patients. The goals of this study are to describe the incidence, medical outcomes, clinical effects, and treatment secondary to tapentadol exposure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS:<\/jats:title>\n                  <jats:p>This retrospective observational study used data from the National Poison Data System. Inclusion criteria were exposure to tapentadol from November 1, 2008 to December 31, 2013; age 0 to 17 years; single ingestion; and followed to a known outcome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS:<\/jats:title>\n                  <jats:p>There were 104 patients who met the inclusion criteria. Eighty patients were aged \u22646, 2-year-olds the most common age group (60.6%). There were 52 male and 52 female patients. Of the 104 patients, 93 had unintentional exposures. No deaths were reported. Sixty-two of the patients had no effect, 34 had minor effects, 6 had moderate and 2 had major effects. Thirty patients reported drowsiness and lethargy. Other effects reported included nausea, vomiting, miosis, tachycardia, respiratory depression, dizziness\/vertigo, coma, dyspnea, pallor, vomiting, edema, hives\/welts, slurred speech, pruritus, and hallucinations\/delusions. Fifty-three patients were reported to have no medical intervention.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS:<\/jats:title>\n                  <jats:p>This is the first study examining the toxic effects of tapentadol in a pediatric population. Although a majority of the patients in this review developed no effect from their exposure, two had life-threatening events. The most common effects reported were opioidlike.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.2014-2096","type":"journal-article","created":{"date-parts":[[2015,1,20]],"date-time":"2015-01-20T03:52:49Z","timestamp":1421725969000},"page":"e392-e396","source":"Crossref","is-referenced-by-count":16,"title":["Tapentadol Toxicity in Children"],"prefix":"10.1542","volume":"135","author":[{"given":"Douglas","family":"Borys","sequence":"first","affiliation":[{"name":"Concordia University Wisconsin, School of Pharmacy, Mequon, Wisconsin;"},{"name":"Wisconsin Poison Center, Milwaukee, Wisconsin;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Stanton","sequence":"additional","affiliation":[{"name":"Wisconsin Poison Center, Milwaukee, Wisconsin;"},{"name":"Froedert Hospital, Department of Emergency Medicine, Milwaukee, Wisconsin; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Gummin","sequence":"additional","affiliation":[{"name":"Wisconsin Poison Center, Milwaukee, Wisconsin;"},{"name":"Children\u2019s Hospital of Wisconsin, Department of Emergency Medicine, Milwaukee, Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy","family":"Drott","sequence":"additional","affiliation":[{"name":"Concordia University Wisconsin, School of Pharmacy, Mequon, Wisconsin;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2015,2,1]]},"reference":[{"volume-title":"Relieving Pain in America, A Blueprint for Transforming Prevention, Care, Education and Research","year":"2003","author":"Institute of Medicine","key":"2021120907031552700_B1"},{"issue":"43","key":"2021120907031552700_B2","first-page":"1487","article-title":"Vital signs: overdoses of prescription opioid pain relievers\u2014United States, 1999\u20132008.","volume":"60","author":"Centers for Disease Control and Prevention (CDC)","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"26","key":"2021120907031552700_B3","first-page":"537","article-title":"Vital signs: overdoses of prescription opioid pain relievers and other drugs among women\u2014United States, 1999\u20132010.","volume":"62","author":"Centers for Disease Control and Prevention (CDC)","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"2021120907031552700_B4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2146\/news090001","article-title":"Tapentadol approved as pain reliever.","volume":"66","author":"Thompson","year":"2009","journal-title":"Am J Health Syst Pharm"},{"issue":"13","key":"2021120907031552700_B5","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2165\/11204470-000000000-00000","article-title":"Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain.","volume":"70","author":"Frampton","year":"2010","journal-title":"Drugs"},{"issue":"3","key":"2021120907031552700_B6","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/11208600-000000000-00000","article-title":"Tapentadol extended release: in adults with chronic pain.","volume":"72","author":"Hoy","year":"2012","journal-title":"Drugs"},{"key":"2021120907031552700_B7"},{"key":"2021120907031552700_B8"},{"issue":"1","key":"2021120907031552700_B9","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1556-4029.2012.02299.x","article-title":"Death due to apparent intravenous injection of tapentadol.","volume":"58","author":"Kemp","year":"2013","journal-title":"J Forensic Sci"},{"issue":"10","key":"2021120907031552700_B10","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3109\/15563650.2013.863906","article-title":"2012 Annual Report of the American Association of Poison Control Centers\u2019 National Poison Data System (NPDS): 30th Annual Report.","volume":"51","author":"Mowry","year":"2013","journal-title":"Clin Toxicol (Phila)"},{"volume-title":"Reference Manual","year":"2014","author":"AAPCC National Poison Data System (NPDS)","key":"2021120907031552700_B11"},{"issue":"5","key":"2021120907031552700_B12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/11589080-000000000-00000","article-title":"Tapentadol in pain management: a \u03bc-opioid receptor agonist and noradrenaline reuptake inhibitor.","volume":"25","author":"Hartrick","year":"2011","journal-title":"CNS Drugs"},{"issue":"12","key":"2021120907031552700_B13","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1016\/j.clinthera.2009.12.003","article-title":"Tapentadol hydrochloride: a centrally acting oral analgesic.","volume":"31","author":"Wade","year":"2009","journal-title":"Clin Ther"},{"issue":"6","key":"2021120907031552700_B14","doi-asserted-by":"crossref","first-page":"395","DOI":"10.5055\/jom.2012.0139","article-title":"Assessment of the abuse of tapentadol immediate release: the first 24 months.","volume":"8","author":"Dart","year":"2012","journal-title":"J Opioid Manag"},{"key":"2021120907031552700_B15","doi-asserted-by":"crossref","unstructured":"Dart RC, Bartelson BB, Adams EH. Non-medical use of tapentadol immediate release by college students. Clin J Pain. 2014;30(8):685\u2013692","DOI":"10.1097\/AJP.0000000000000001"},{"issue":"1","key":"2021120907031552700_B16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.annemergmed.2011.08.004","article-title":"Using poison center data for national public health surveillance for chemical and poison exposure and associated illness.","volume":"59","author":"Wolkin","year":"2012","journal-title":"Ann Emerg Med"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/135\/2\/e392\/1058141\/peds_2014-2096.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/135\/2\/e392\/1058141\/peds_2014-2096.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T01:24:55Z","timestamp":1639099495000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/135\/2\/e392\/33489\/Tapentadol-Toxicity-in-Children"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,1]]},"references-count":16,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,2,1]]},"published-print":{"date-parts":[[2015,2,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2014-2096","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"type":"print","value":"0031-4005"},{"type":"electronic","value":"1098-4275"}],"subject":[],"published":{"date-parts":[[2015,2,1]]}}}